The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Chronic Myeloid Leukemia Treatment Drugs Market Research Report 2025
Synopsis
Chronic myeloid leukemia (CML) is a type of cancer that starts in certain blood-forming cells of the bone marrow. It most commonly occurs in the adults and very rarely it occurs in children. Chronic myeloid leukemia usually begins after age 60. CML is develop slowly and treated with targeted cancer drugs such as tyrosine kinase inhibitors, chemotherapy or a bone marrow transplant. Recent advances in cancer treatments has drastically improved the survival rate for this type of leukemia.
Global Chronic Myeloid Leukemia Treatment Drugs market is projected to reach US$ 944.9 million in 2029, increasing from US$ 718 million in 2022, with the CAGR of 4.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Chronic Myeloid Leukemia Treatment Drugs market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Chronic Myeloid Leukemia Treatment Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Teva Pharmaceutical Industries Ltd
F. Hoffmann-La Roche Ltd.
Novartis AG
Bristol-Myers Squibb Company
Pfizer Inc.
Takeda Pharmaceutical Company Limited
Innovent Biologics, Inc.
Viatris Inc. (Mylan N.V.)
Lupin
IL-YANG PHARM CO. LTD.
Million Health Pharmaceuticals
Celon Labs
Segment by Type
Tablet
Solution
Capsule
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Chronic Myeloid Leukemia Treatment Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Chronic myeloid leukemia (CML) is a type of cancer that starts in certain blood-forming cells of the bone marrow. It most commonly occurs in the adults and very rarely it occurs in children. Chronic myeloid leukemia usually begins after age 60. CML is develop slowly and treated with targeted cancer drugs such as tyrosine kinase inhibitors, chemotherapy or a bone marrow transplant. Recent advances in cancer treatments has drastically improved the survival rate for this type of leukemia.
Global Chronic Myeloid Leukemia Treatment Drugs market is projected to reach US$ 944.9 million in 2029, increasing from US$ 718 million in 2022, with the CAGR of 4.3% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Chronic Myeloid Leukemia Treatment Drugs market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Chronic Myeloid Leukemia Treatment Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Teva Pharmaceutical Industries Ltd
F. Hoffmann-La Roche Ltd.
Novartis AG
Bristol-Myers Squibb Company
Pfizer Inc.
Takeda Pharmaceutical Company Limited
Innovent Biologics, Inc.
Viatris Inc. (Mylan N.V.)
Lupin
IL-YANG PHARM CO. LTD.
Million Health Pharmaceuticals
Celon Labs
Segment by Type
Tablet
Solution
Capsule
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Chronic Myeloid Leukemia Treatment Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Chronic Myeloid Leukemia Treatment Drugs Market Overview
1.1 Product Overview and Scope of Chronic Myeloid Leukemia Treatment Drugs
1.2 Chronic Myeloid Leukemia Treatment Drugs Segment by Type
1.2.1 Global Chronic Myeloid Leukemia Treatment Drugs Market Value Comparison by Type (2023-2029)
1.2.2 Tablet
1.2.3 Solution
1.2.4 Capsule
1.3 Chronic Myeloid Leukemia Treatment Drugs Segment by Application
1.3.1 Global Chronic Myeloid Leukemia Treatment Drugs Market Value by Application: (2023-2029)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Chronic Myeloid Leukemia Treatment Drugs Market Size Estimates and Forecasts
1.4.1 Global Chronic Myeloid Leukemia Treatment Drugs Revenue 2018-2029
1.4.2 Global Chronic Myeloid Leukemia Treatment Drugs Sales 2018-2029
1.4.3 Global Chronic Myeloid Leukemia Treatment Drugs Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Chronic Myeloid Leukemia Treatment Drugs Market Competition by Manufacturers
2.1 Global Chronic Myeloid Leukemia Treatment Drugs Sales Market Share by Manufacturers (2018-2023)
2.2 Global Chronic Myeloid Leukemia Treatment Drugs Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Chronic Myeloid Leukemia Treatment Drugs Average Price by Manufacturers (2018-2023)
2.4 Global Chronic Myeloid Leukemia Treatment Drugs Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Chronic Myeloid Leukemia Treatment Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Chronic Myeloid Leukemia Treatment Drugs, Product Type & Application
2.7 Chronic Myeloid Leukemia Treatment Drugs Market Competitive Situation and Trends
2.7.1 Chronic Myeloid Leukemia Treatment Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Chronic Myeloid Leukemia Treatment Drugs Players Market Share by Revenue
2.7.3 Global Chronic Myeloid Leukemia Treatment Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Chronic Myeloid Leukemia Treatment Drugs Retrospective Market Scenario by Region
3.1 Global Chronic Myeloid Leukemia Treatment Drugs Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Chronic Myeloid Leukemia Treatment Drugs Global Chronic Myeloid Leukemia Treatment Drugs Sales by Region: 2018-2029
3.2.1 Global Chronic Myeloid Leukemia Treatment Drugs Sales by Region: 2018-2023
3.2.2 Global Chronic Myeloid Leukemia Treatment Drugs Sales by Region: 2024-2029
3.3 Global Chronic Myeloid Leukemia Treatment Drugs Global Chronic Myeloid Leukemia Treatment Drugs Revenue by Region: 2018-2029
3.3.1 Global Chronic Myeloid Leukemia Treatment Drugs Revenue by Region: 2018-2023
3.3.2 Global Chronic Myeloid Leukemia Treatment Drugs Revenue by Region: 2024-2029
3.4 North America Chronic Myeloid Leukemia Treatment Drugs Market Facts & Figures by Country
3.4.1 North America Chronic Myeloid Leukemia Treatment Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Chronic Myeloid Leukemia Treatment Drugs Sales by Country (2018-2029)
3.4.3 North America Chronic Myeloid Leukemia Treatment Drugs Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Chronic Myeloid Leukemia Treatment Drugs Market Facts & Figures by Country
3.5.1 Europe Chronic Myeloid Leukemia Treatment Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Chronic Myeloid Leukemia Treatment Drugs Sales by Country (2018-2029)
3.5.3 Europe Chronic Myeloid Leukemia Treatment Drugs Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Chronic Myeloid Leukemia Treatment Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Chronic Myeloid Leukemia Treatment Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Chronic Myeloid Leukemia Treatment Drugs Sales by Country (2018-2029)
3.6.3 Asia Pacific Chronic Myeloid Leukemia Treatment Drugs Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Chronic Myeloid Leukemia Treatment Drugs Market Facts & Figures by Country
3.7.1 Latin America Chronic Myeloid Leukemia Treatment Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Chronic Myeloid Leukemia Treatment Drugs Sales by Country (2018-2029)
3.7.3 Latin America Chronic Myeloid Leukemia Treatment Drugs Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Chronic Myeloid Leukemia Treatment Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Chronic Myeloid Leukemia Treatment Drugs Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Chronic Myeloid Leukemia Treatment Drugs Sales by Country (2018-2029)
3.8.3 Middle East and Africa Chronic Myeloid Leukemia Treatment Drugs Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Chronic Myeloid Leukemia Treatment Drugs Sales by Type (2018-2029)
4.1.1 Global Chronic Myeloid Leukemia Treatment Drugs Sales by Type (2018-2023)
4.1.2 Global Chronic Myeloid Leukemia Treatment Drugs Sales by Type (2024-2029)
4.1.3 Global Chronic Myeloid Leukemia Treatment Drugs Sales Market Share by Type (2018-2029)
4.2 Global Chronic Myeloid Leukemia Treatment Drugs Revenue by Type (2018-2029)
4.2.1 Global Chronic Myeloid Leukemia Treatment Drugs Revenue by Type (2018-2023)
4.2.2 Global Chronic Myeloid Leukemia Treatment Drugs Revenue by Type (2024-2029)
4.2.3 Global Chronic Myeloid Leukemia Treatment Drugs Revenue Market Share by Type (2018-2029)
4.3 Global Chronic Myeloid Leukemia Treatment Drugs Price by Type (2018-2029)
5 Segment by Application
5.1 Global Chronic Myeloid Leukemia Treatment Drugs Sales by Application (2018-2029)
5.1.1 Global Chronic Myeloid Leukemia Treatment Drugs Sales by Application (2018-2023)
5.1.2 Global Chronic Myeloid Leukemia Treatment Drugs Sales by Application (2024-2029)
5.1.3 Global Chronic Myeloid Leukemia Treatment Drugs Sales Market Share by Application (2018-2029)
5.2 Global Chronic Myeloid Leukemia Treatment Drugs Revenue by Application (2018-2029)
5.2.1 Global Chronic Myeloid Leukemia Treatment Drugs Revenue by Application (2018-2023)
5.2.2 Global Chronic Myeloid Leukemia Treatment Drugs Revenue by Application (2024-2029)
5.2.3 Global Chronic Myeloid Leukemia Treatment Drugs Revenue Market Share by Application (2018-2029)
5.3 Global Chronic Myeloid Leukemia Treatment Drugs Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Teva Pharmaceutical Industries Ltd
6.1.1 Teva Pharmaceutical Industries Ltd Corporation Information
6.1.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
6.1.3 Teva Pharmaceutical Industries Ltd Chronic Myeloid Leukemia Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Teva Pharmaceutical Industries Ltd Chronic Myeloid Leukemia Treatment Drugs Product Portfolio
6.1.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 F. Hoffmann-La Roche Ltd. Corporation Information
6.2.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
6.2.3 F. Hoffmann-La Roche Ltd. Chronic Myeloid Leukemia Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.2.4 F. Hoffmann-La Roche Ltd. Chronic Myeloid Leukemia Treatment Drugs Product Portfolio
6.2.5 F. Hoffmann-La Roche Ltd. Recent Developments/Updates
6.3 Novartis AG
6.3.1 Novartis AG Corporation Information
6.3.2 Novartis AG Description and Business Overview
6.3.3 Novartis AG Chronic Myeloid Leukemia Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Novartis AG Chronic Myeloid Leukemia Treatment Drugs Product Portfolio
6.3.5 Novartis AG Recent Developments/Updates
6.4 Bristol-Myers Squibb Company
6.4.1 Bristol-Myers Squibb Company Corporation Information
6.4.2 Bristol-Myers Squibb Company Description and Business Overview
6.4.3 Bristol-Myers Squibb Company Chronic Myeloid Leukemia Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Bristol-Myers Squibb Company Chronic Myeloid Leukemia Treatment Drugs Product Portfolio
6.4.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.5 Pfizer Inc.
6.5.1 Pfizer Inc. Corporation Information
6.5.2 Pfizer Inc. Description and Business Overview
6.5.3 Pfizer Inc. Chronic Myeloid Leukemia Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Pfizer Inc. Chronic Myeloid Leukemia Treatment Drugs Product Portfolio
6.5.5 Pfizer Inc. Recent Developments/Updates
6.6 Takeda Pharmaceutical Company Limited
6.6.1 Takeda Pharmaceutical Company Limited Corporation Information
6.6.2 Takeda Pharmaceutical Company Limited Description and Business Overview
6.6.3 Takeda Pharmaceutical Company Limited Chronic Myeloid Leukemia Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Takeda Pharmaceutical Company Limited Chronic Myeloid Leukemia Treatment Drugs Product Portfolio
6.6.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
6.7 Innovent Biologics, Inc.
6.6.1 Innovent Biologics, Inc. Corporation Information
6.6.2 Innovent Biologics, Inc. Description and Business Overview
6.6.3 Innovent Biologics, Inc. Chronic Myeloid Leukemia Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Innovent Biologics, Inc. Chronic Myeloid Leukemia Treatment Drugs Product Portfolio
6.7.5 Innovent Biologics, Inc. Recent Developments/Updates
6.8 Viatris Inc. (Mylan N.V.)
6.8.1 Viatris Inc. (Mylan N.V.) Corporation Information
6.8.2 Viatris Inc. (Mylan N.V.) Description and Business Overview
6.8.3 Viatris Inc. (Mylan N.V.) Chronic Myeloid Leukemia Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Viatris Inc. (Mylan N.V.) Chronic Myeloid Leukemia Treatment Drugs Product Portfolio
6.8.5 Viatris Inc. (Mylan N.V.) Recent Developments/Updates
6.9 Lupin
6.9.1 Lupin Corporation Information
6.9.2 Lupin Description and Business Overview
6.9.3 Lupin Chronic Myeloid Leukemia Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Lupin Chronic Myeloid Leukemia Treatment Drugs Product Portfolio
6.9.5 Lupin Recent Developments/Updates
6.10 IL-YANG PHARM CO. LTD.
6.10.1 IL-YANG PHARM CO. LTD. Corporation Information
6.10.2 IL-YANG PHARM CO. LTD. Description and Business Overview
6.10.3 IL-YANG PHARM CO. LTD. Chronic Myeloid Leukemia Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.10.4 IL-YANG PHARM CO. LTD. Chronic Myeloid Leukemia Treatment Drugs Product Portfolio
6.10.5 IL-YANG PHARM CO. LTD. Recent Developments/Updates
6.11 Million Health Pharmaceuticals
6.11.1 Million Health Pharmaceuticals Corporation Information
6.11.2 Million Health Pharmaceuticals Chronic Myeloid Leukemia Treatment Drugs Description and Business Overview
6.11.3 Million Health Pharmaceuticals Chronic Myeloid Leukemia Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Million Health Pharmaceuticals Chronic Myeloid Leukemia Treatment Drugs Product Portfolio
6.11.5 Million Health Pharmaceuticals Recent Developments/Updates
6.12 Celon Labs
6.12.1 Celon Labs Corporation Information
6.12.2 Celon Labs Chronic Myeloid Leukemia Treatment Drugs Description and Business Overview
6.12.3 Celon Labs Chronic Myeloid Leukemia Treatment Drugs Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Celon Labs Chronic Myeloid Leukemia Treatment Drugs Product Portfolio
6.12.5 Celon Labs Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Chronic Myeloid Leukemia Treatment Drugs Industry Chain Analysis
7.2 Chronic Myeloid Leukemia Treatment Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Chronic Myeloid Leukemia Treatment Drugs Production Mode & Process
7.4 Chronic Myeloid Leukemia Treatment Drugs Sales and Marketing
7.4.1 Chronic Myeloid Leukemia Treatment Drugs Sales Channels
7.4.2 Chronic Myeloid Leukemia Treatment Drugs Distributors
7.5 Chronic Myeloid Leukemia Treatment Drugs Customers
8 Chronic Myeloid Leukemia Treatment Drugs Market Dynamics
8.1 Chronic Myeloid Leukemia Treatment Drugs Industry Trends
8.2 Chronic Myeloid Leukemia Treatment Drugs Market Drivers
8.3 Chronic Myeloid Leukemia Treatment Drugs Market Challenges
8.4 Chronic Myeloid Leukemia Treatment Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
